About Us

Ben Gonzales, SVP Commercial at Inoviv, spearheads business development, marketing, and product strategy for the company’s fully validated, multiplexed, mass spectrometry-based proteomics assays. With over 20 years of leadership in biotech and pharma, Ben specializes in proteomics, having successfully developed and commercialized innovative technologies in diagnostics and R&D. Previously, he served as General Manager at Biognosys Inc., expanding US operations in support of mass spectrometry-based proteomics. Ben’s career also includes pivotal roles such as Product Manager at SomaLogic, where he contributed to the commercialization of cutting-edge technologies. His expertise drives Inoviv’s growth and leadership in proteomics solutions.

Amundeep Dhanoa is our Director of People & Operations, with 15+ years of experience in high-growth, mission driven, investor backed SMEs. With responsibility for Inoviv’s People, Finance and Operations functions she brings a focus on developing inclusive, high-performance cultures and designing scalable, tech-enabled processes which boost productivity and growth. She previously worked at The Key, where she successfully supported the company to scale from 20 to 300 employees across 8 offices. She is passionate about people, building winning teams and using technology and data with purpose.

Lucy-Rose is a visionary leader and entrepreneur with a proven track record of fostering innovation and empowering entrepreneurs. Prior to joining Inoviv as our People Advisor, Lucy-Rose served as the Chief Entrepreneuring Officer (CEO) at Entrepreneurial Spark, where she started, grew, and sold the largest fully funded entrepreneuring accelerator in the UK. Over seven years, she scaled the organization to 13 locations across the UK, supporting over 4000 entrepreneurs and leading a team of 44. During this period, Lucy-Rose played a pivotal role in establishing the organization as a nationwide non-sector specific free startup business accelerator. Through ideation, mentoring, and ambassador programs, she enabled startups to increase their probability of becoming investable, sustainable, and scalable.

Jacob leads the Global Business Development Team at Inoviv, bringing 5+ years of invaluable experience to the table. His tenure at Inoviv has been marked by pioneering efforts in implementing the use of biomarkers in clinical trials across neurodegeneration, fibrosis, oncology and others. With a background in Biochemistry from Imperial College London coupled with experience in Investment Banking/M&A at Goldman Sachs, Jacob offers a unique blend of scientific acumen and business expertise. Passionate about generating key insights to accelerate the development of new medicines, Jacob is dedicated to driving innovation and forging strategic partnerships that advance healthcare outcomes.

Andrew is a seasoned professional with a diverse background in scientific innovation and business leadership. Prior to joining Inoviv as the Director of Discovery & Technology, Andrew served as Head of Chemical Proteomics at Proteome Sciences, where he led groundbreaking initiatives in the development of the “TMT-pro-16-plex”, a significant advancement in mass spectrometry-based proteomics. His efforts in optimizing workflows and expanding the product pipeline contributed to strengthening the company’s position in the market. Additionally, Andrew also served as the Chief Scientific Officer at Trillion Genomics, where he led the creation of a diverse product portfolio. He spearheaded the development of novel technologies, including MALDI Imaging tags, LNA Discontinuous Probes, and asymmetric PCR methods, aimed at high-specificity diagnostics and antisense targeting applications.

Martin is an accomplished professional with extensive experience in bioanalysis and mass spectrometry. Currently serving as the Director of Bioanalysis at Inoviv, Martin brings a wealth of knowledge and expertise to his role. Prior to joining Inoviv, Martin served as Lead Scientist at Medicines Discovery Catapult, where he established a high-throughput mass spectrometry laboratory and played a key role in developing innovative solutions for complex analytical challenges in drug discovery and biomarker research. Martin also contributed to innovative projects as a Postdoctoral Scientist at AstraZeneca, where he played a pivotal role in the design and development of Acoustic Mist Ionisation MS (AMI-MS), a cutting-edge analytical platform that revolutionized drug discovery efforts.

Blandine is a seasoned professional with over a decade of experience in protein analysis and quantification via mass spectrometry. She has worked across diverse industries including diagnostics, pharmaceuticals, and agriculture. Before joining Inoviv as associate director of Analysis, she held technical expert roles in various companies such as BioMerieux, Sanofi Pasteur, UCB Pharma, and Syngenta. Her expertise lies in utilizing targeted and global proteomics quantitative workflows to identify biomarkers, metabolic pathways, and mechanisms of action for new molecules. Notable highlights of her career include her doctoral research at Université Claude-Bernard-Lyon-I, focusing on targeted proteomics for vaccine integrity monitoring in collaboration with Sanofi Pasteur, and her work with Sciex on novel approaches for highly multiplexed targeted mass spectrometry datasets.

Currently serving as our Director of Bioinformatics, Craig brings a wealth of experience in programming, statistical analysis and big data. Craig’s bioinformatics journey spans over decades, most notably at the University of Manchester, where he held various roles including Bioinformatics Senior Experimental Officer at the Wellcome Trust Centre for Cell Matrix Research and spearheaded the Wellcome Trust’s multi-million-dollar discovery bioinformatics strategy. Furthermore, Craig has also developed tools for surrogate peptide selection in quantitative proteomics and designed pipelines for QconCAT technology, enabling absolute protein quantification in yeast. Craig’s expertise also extends to processing and analyzing mass spectrometry data using various pipelines (mProphet, Skyline, MaxQuant, Progenesis, PLGS, Mass Lynx, DanteR), as well as next-generation RNA-sequencing analysis.

Rocky is one of our most loyal team members, ranked #1, good boy.